These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 22768914)

  • 1. Antiandrogen gold nanoparticles dual-target and overcome treatment resistance in hormone-insensitive prostate cancer cells.
    Dreaden EC; Gryder BE; Austin LA; Tene Defo BA; Hayden SC; Pi M; Quarles LD; Oyelere AK; El-Sayed MA
    Bioconjug Chem; 2012 Aug; 23(8):1507-12. PubMed ID: 22768914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a potent antiandrogen that targets the BF3 site of the androgen receptor and inhibits enzalutamide-resistant prostate cancer.
    Munuganti RS; Hassona MD; Leblanc E; Frewin K; Singh K; Ma D; Ban F; Hsing M; Adomat H; Lallous N; Andre C; Jonadass JP; Zoubeidi A; Young RN; Guns ET; Rennie PS; Cherkasov A
    Chem Biol; 2014 Nov; 21(11):1476-85. PubMed ID: 25459660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement in Therapeutic Efficacy and Reduction in Cellular Toxicity: Introduction of a Novel Anti-PSMA-Conjugated Hybrid Antiandrogen Nanoparticle.
    Thangavel C; Perepelyuk M; Boopathi E; Liu Y; Polischak S; Deshpande DA; Rafiq K; Dicker AP; Knudsen KE; Shoyele SA; Den RB
    Mol Pharm; 2018 May; 15(5):1778-1790. PubMed ID: 29616555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multivalent Peptoid Conjugates Which Overcome Enzalutamide Resistance in Prostate Cancer Cells.
    Wang Y; Dehigaspitiya DC; Levine PM; Profit AA; Haugbro M; Imberg-Kazdan K; Logan SK; Kirshenbaum K; Garabedian MJ
    Cancer Res; 2016 Sep; 76(17):5124-32. PubMed ID: 27488525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiandrogens in prostate cancer.
    Reid P; Kantoff P; Oh W
    Invest New Drugs; 1999; 17(3):271-84. PubMed ID: 10665479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased expression of activated endothelial nitric oxide synthase contributes to antiandrogen resistance in prostate cancer cells by suppressing androgen receptor transactivation.
    Yu S; Jia L; Zhang Y; Wu D; Xu Z; Ng CF; To KK; Huang Y; Chan FL
    Cancer Lett; 2013 Jan; 328(1):83-94. PubMed ID: 22995070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiandrogens in prostate cancer endocrine therapy.
    Culig Z; Bartsch G; Hobisch A
    Curr Cancer Drug Targets; 2004 Aug; 4(5):455-61. PubMed ID: 15320720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells.
    Gaur S; Gross ME; Liao CP; Qian B; Shih JC
    Prostate; 2019 May; 79(6):667-677. PubMed ID: 30693539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular determinants of resistance to antiandrogen therapy.
    Chen CD; Welsbie DS; Tran C; Baek SH; Chen R; Vessella R; Rosenfeld MG; Sawyers CL
    Nat Med; 2004 Jan; 10(1):33-9. PubMed ID: 14702632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor plasticity and its implications for prostate cancer therapy.
    Snow O; Lallous N; Singh K; Lack N; Rennie P; Cherkasov A
    Cancer Treat Rev; 2019 Dec; 81():101871. PubMed ID: 31698174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
    Tran C; Ouk S; Clegg NJ; Chen Y; Watson PA; Arora V; Wongvipat J; Smith-Jones PM; Yoo D; Kwon A; Wasielewska T; Welsbie D; Chen CD; Higano CS; Beer TM; Hung DT; Scher HI; Jung ME; Sawyers CL
    Science; 2009 May; 324(5928):787-90. PubMed ID: 19359544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The androgen receptor as putative therapeutic target in hormone-refractory prostate cancer.
    Kageyama Y; Hyochi N; Kihara K; Sugiyama H
    Recent Pat Anticancer Drug Discov; 2007 Nov; 2(3):203-11. PubMed ID: 18221063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.
    Crawford ED; Schellhammer PF; McLeod DG; Moul JW; Higano CS; Shore N; Denis L; Iversen P; Eisenberger MA; Labrie F
    J Urol; 2018 Nov; 200(5):956-966. PubMed ID: 29730201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens.
    Whitaker HC; Hanrahan S; Totty N; Gamble SC; Waxman J; Cato AC; Hurst HC; Bevan CL
    Clin Cancer Res; 2004 Nov; 10(21):7392-401. PubMed ID: 15534116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ADT with antiandrogens in prostate cancer induces adverse effect of increasing resistance, neuroendocrine differentiation and tumor metastasis.
    Niu Y; Guo C; Wen S; Tian J; Luo J; Wang K; Tian H; Yeh S; Chang C
    Cancer Lett; 2018 Dec; 439():47-55. PubMed ID: 30227222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cigarette smoking augments androgen receptor activity and promotes resistance to antiandrogen therapy.
    Shiota M; Ushijima M; Imada K; Kashiwagi E; Takeuchi A; Inokuchi J; Tatsugami K; Kajioka S; Eto M
    Prostate; 2019 Jul; 79(10):1147-1155. PubMed ID: 31077419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A molecule inducing androgen receptor degradation and selectively targeting prostate cancer cells.
    Auvin S; Öztürk H; Abaci YT; Mautino G; Meyer-Losic F; Jollivet F; Bashir T; de Thé H; Sahin U
    Life Sci Alliance; 2019 Aug; 2(4):. PubMed ID: 31431473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The development of Casodex (bicalutamide): preclinical studies.
    Furr BJ
    Eur Urol; 1996; 29 Suppl 2():83-95. PubMed ID: 8717469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational design of novel antiandrogens for neutralizing androgen receptor function in hormone refractory prostate cancer.
    Singh P; Hallur G; Anchoori RK; Bakare O; Kageyama Y; Khan SR; Isaacs JT
    Prostate; 2008 Oct; 68(14):1570-81. PubMed ID: 18668523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.